TAK-931

CDC7 serine/threonine kinase inhibitor

oral 50 mg QD, Ph. II in solid tumors compl.

from homology model pharmacophore + opt.

Sci. Adv., May 21, 2021

Takeda Pharmaceutical, Kanagawa, JP

The Takeda CDC7 serine/threonine kinase inhibitor, simurosertib (TAK-931), is the first orally active CDC7-selective inhibitor and recently had its Ph. I study results in solid tumors posted. The drug was…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks